Misoprostol for Non-Viable Pregnancies

Completed · Phase 3 · Has a placebo group

Conditions studied: Abortifacient Agents, Nonsteroidal, Abortion, Incomplete, Misoprostol, Pregnancy

In brief

The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects.

Key facts

Study ID

NCT00426491

Run by

Madigan Army Medical Center

People needed

30

Starts

1999-03-01

Expected to finish

2006-10-01

Last updated by the study team

2008-02-08

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Pregnant patients with nonviable pregnancy document by ultrasound
• Gestation at or less than 13 weeks by ultrasound measurements
• Clinically stable as determined by provider
• Afebrile
• Hematocrit > 30
• Over 18 years of age

You may not qualify if…

• History of allergy to, or intolerance of, misoprostol
• Refusal to abstain from intercourse for 72 hours
• Significant vaginal bleeding (> 2 pad/hr)
• History of inflammatory bowel disease

Where it is running

• Madigan Army Medical Center — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.